Octagam (Human Normal Immunoglobulin)

Octagam is an immunoglobulin therapy that modulates immune function in several clinical settings.

• Primary immunodeficiency diseases: provides essential antibodies to reduce infection frequency.
• Chronic inflammatory demyelinating polyneuropathy (CIDP): helps restore nerve function and lessen disability.
• Multifactorial immune thrombocytopenia (ITP): raises platelet counts and decreases bleeding risk.

• Octagam contains pooled human IgG antibodies that bind to a broad spectrum of antigens, neutralising pathogens and modulating immune cell activity. The preparation also interferes with complement activation and Fc‑receptor mediated processes, thereby reducing auto‑antibody‑driven inflammation and restoring immune homeostasis.

Adverse reactions to Octagam vary from mild to severe and are monitored throughout therapy.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Fever or chills: typical infusion‑related response.
• Nausea or vomiting: usually resolves after the infusion ends.
• Fatigue: general tiredness during or after administration.
• Injection site erythema: localized redness at the catheter site.
• Hypertension: temporary rise in blood pressure during infusion.

Serious or Rare Side Effects

• Anaphylaxis: acute, life‑threatening allergic reaction requiring immediate medical intervention.
• Acute renal failure: sudden loss of kidney function, especially in patients with pre‑existing renal disease.
• Thromboembolic events: clot formation that can affect veins or arteries.
• Hemolytic anemia: destruction of red blood cells leading to anemia.
• Aseptic meningitis: inflammation of the meninges without infection.
• Severe transfusion‑related acute lung injury (TRALI): acute respiratory distress following infusion.

Before initiating Octagam therapy, clinicians should evaluate patient history and monitor for specific risks.

• Assess renal function: baseline creatinine and eGFR are required.
• Screen for thrombotic risk: consider history of clotting disorders.
• Evaluate for IgA deficiency: patients with anti‑IgA antibodies may develop severe reactions.
• Monitor blood pressure: watch for hypertension during infusion.
• Observe for signs of infection: ensure active infections are treated before infusion.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octagam may interact with other agents that affect immune function or coagulation.

Major Interactions (Avoid)

• Live vaccines: concurrent administration can reduce vaccine efficacy and increase adverse events.
• High‑dose aspirin or anticoagulants: heightened risk of bleeding complications.

Moderate Interactions (Monitor Closely)

• Immunosuppressive biologics (e.g., rituximab): may alter therapeutic response.
• Corticosteroids: can increase infection risk when combined.
• ACE inhibitors: may potentiate infusion‑related hypertension.
• Diuretics: monitor fluid balance and renal function.
• Antiviral agents (e.g., ganciclovir): watch for additive nephrotoxicity.